MELISSA ANDRADE: Open Payments
NPI 1801339163 · EDMOND, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,489 in 73 payments from 12 companies in 2025. Trend: 2023 $2,335 · 2024 $1,788 · 2025 $1,489
Food & beverage: $1,377Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 14 | $306 |
| Vanda Pharmaceuticals Inc. | 15 | $294 |
| Otsuka America Pharmaceutical, Inc. | 12 | $293 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $199 |
| Neurocrine BioSciences, Inc. | 5 | $90 |
| Supernus Pharmaceuticals, Inc. | 3 | $65 |
| Janssen Pharmaceuticals, Inc | 3 | $52 |
| Alkermes, Inc. | 2 | $45 |
| ABBVIE INC. | 3 | $45 |
| Collegium Pharmaceutical, Inc. | 2 | $41 |
Products named: FANAPT, REXULTI, CAPLYTA, AUSTEDO XR, INGREZZA, UZEDY, Qelbree, SPRAVATO.
Industry payments across OK — which companies pay providers there.
